The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Virtual Clinical Trial Service Providers Market by Type of Therapeutic Area (Cardiovascular disorders, Infectious disorders, Metabolic disorders, Neurological disorders, Oncological disorders and Other disorders), End-Users (Small-sized players, Mid-sized players, Large players and Academia / Others), Phase of Development (Phase I, Phase II, Phase III and Phase IV), and Key Geographies (North America, Europe, Asia Pacific, and Rest of the World): Industry Trends and Global Forecasts, 2020-2050

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    250

  • View Count
    525

Example Insights

Virtual-Clinical-Trial-Service-Providers-Market-Context Virtual-Clinical-Trial-Service-Providers-Market-Distribution-by-Type-of-Service Virtual-Clinical-Trial-Service-Providers-Market-Regional-Landscape
Virtual-Clinical-Trial-Service-Providers-Market-Funding-and-Investments Virtual-Clinical-Trial-Service-Providers-Market-Key-Developments Virtual-Clinical-Trial-Service-Providers-Market-Clinical-Trial-Analysis
Virtual-Clinical-Trial-Service-Providers-Market-Partnerships-and-Collabarations Virtual-Clinical-Trial-Service-Providers-Market-Distribution-by-Therapeutic-Area Virtual-Clinical-Trial-Service-Providers-Market-Market-Forecast

 

Overview

Owing to its highly cost and time intensive nature, the development of a novel molecular entity is a complex and sophisticated process. In fact, it is estimated that before receiving regulatory approval, a prescription drug requires more than 10 years and close to USD 3 billion in capital investment. Additionally, close to 40% of the pharmaceutical industry’s R&D budget in the US is spent on conducting clinical trials assessing the efficacy of novel treatments. With rising geographical diversity in clinical trials, the trial complexity is increasing rapidly in this domain making it difficult for trial coordinators to identify sub-optimal trial sites. It is worth highlighting that, the clinical research process is known to be prone to delays, and often faces several other challenges, including (but not limited to) inefficient data handling, risk of failure and incomplete patient recruitment, which can be validated from the fact that only 10% of drug candidates under clinical development receive regulatory approval. The lack of patient centricity in traditional clinical trials inhibit trial sponsors to retain enough patients, which is critical to successfully conduct clinical research on predetermined completion dates. The lack of participant compliance in clinical trials often leads to massive delays which are known to impose enormous financial burden on sponsors, amounting close to USD 8 million, per day, blockbuster drugs. Another noticeable concern in this domain, is the inefficient handling of clinical data, which is primarily due insignificant use electronic health records. Estimates indicate that, the pharmaceutical industry incurs losses of USD 6 billion each year due to such avoidable data-related concerns. In addition, the COVID-19 pandemic has impacted nearly all aspects of clinical operations being conducted across the world.

Over the years, the pharmaceutical industry has leveraged technological advances to address several of the aforementioned clinical trial-related constraints / challenges. In fact, the clinical research segment has recently witnessed participation of several vendors, offering wide range of services and solutions for conducting and managing various aspects of trials. Virtual clinical trials have demonstrated the potential to disrupt the conventional ways of conducting trials, allowing sponsors to establish a more patient centric approach to drug development. Virtual clinical trial technologies augment clinical research by implementation of advanced technological solutions, including (but not limited to) software applications, e-monitoring devices and social engagement platforms. Such solutions hold the potential to save up to 25% of capital invested in clinical trials, by enabling efficient patient recruitment, reduction in patient attrition rate and robust data analysis. It is worth noting that, virtual trials related initiatives have also received significant funding from both private and public investors. With digital solutions witnessing increased adoption in the drug development process, we are led to believe that the virtual clinical trials market is likely to grow significantly in the coming years.

Scope of the Report

The ‘Virtual Clinical Trial Service Providers Market, 2020-2050’ report features an extensive study of the current landscape of industry players that are offering various types of innovative clinical research platforms / solutions to the pharmaceutical and life sciences industries. Amongst other elements, the report features:

  • An overview of the current market landscape of companies offering solutions for virtual clinical trials, featuring information on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention).
  • Brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.
  • A case study on the initiatives of big pharma players related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.
  • An analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.
  • An analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, type of partner, most active players and geographical analysis. 
  • A detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model. 
  • A brief case study highlighting the impact of COVID-19 pandemic on virtual clinical trial service providers market.
  • A detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity of the market for virtual clinical trial services. Based on parameters, such as number of pre- or post-approval studies conducted annually, capital investments made in these studies, and the likely cost and time saving opportunities, we have provided an informed estimate of the likely evolution of the market for virtual clinical trials, for the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] end-users (small-sized players, mid-sized players, large players and academia / others) [C] phase of development (phase I, phase II, phase III and phase IV) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Phillipe Lemmens (Chief Operating Officer, Andaman7)
  • Himanshu Verma (Founder and Chief Executive Officer, ConsilX) and Rajesh Jain (Co-Founder, ConsilX)
  • Greg Erman (President and Chief Executive Officer, EmpiraMed)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading virtual clinical trial service providers?
  • Which companies have raised significant capital in this domain?
  • How can traditional CRO transition to virtual CRO?
  • What factors are likely to influence the evolution of this upcoming market?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the virtual clinical trial service providers market, in the mid to long term.

Chapter 3 presents a general overview of the investment, in terms of time and cost, required for developing new healthcare products, along with information on other constraints associated with clinical research, including patient recruitment and retention, evolving regulatory standards and inefficient data handling. Further, it features a detailed outline on the various upcoming trends that are anticipated to play a crucial role in shaping the future of clinical trials, including increasing focus on patient centricity, precision medicine, real-world evidence, big data analytics, virtual clinical trials, innovative trial designs and blockchain-based platforms.

Chapter 4 provides a list of industry players that are actively involved in offering services for virtual clinical trials. The chapter presents analyses of these players based on year of establishment, geographical location, company size and types of services offered (study start-up, patient enrollment, drug logistics, data collection and analysis, and patient retention). 

Chapter 5 features brief profiles of companies offering solutions for virtual clinical trials, featuring information on their year of establishment, respective headquarters, company size, key executives, service / technology portfolio, recent developments and an informed future outlook.

Chapter 6 is a case study on the initiatives of big pharma companies related to virtual clinical trials, offering insights on such clinical studies that have been conducted / planned by the aforementioned players, along with details on associated constraints and the future plans of players engaged in this domain.

Chapter 7 provides an analysis of the funding and investments made in the domain, in the period between 2014 and 2020 (till November), including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in companies that are engaged in this field, based on several parameters, such as number of funding instances, amount invested, type of funding, leading players and investors, and geographical analysis.

Chapter 8 provides an analysis of the partnerships and collaborations inked in the domain, in the period between 2014 and 2020 (till November), based on several parameters, such as year of partnership, type of partnership, application mentioned in agreement, target therapeutic area mentioned in the agreement, year of partnership and type of partner, most active players and geographical analysis.  

Chapter 9 provides a detailed study highlighting the key differences between traditional and virtual CROs and an elaborate road map, presenting the requirements for a traditional CRO to transition to a virtual CRO business model.

Chapter 10 provides an insightful discussion on the impact of COVID-19 pandemic on the virtual clinical trial service providers market. 

Chapter 11 provides a detailed analysis of completed, ongoing and planned virtual clinical trials, based on multiple parameters, such as trial registration year, trial phase, trial status, type of sponsor / collaborator, target therapeutic area, trial design, top sponsor, geographical location of trial and enrolled patient population.

Chapter 12 provides an insightful opportunity analysis, estimating the existing market size and potential growth opportunities across service providers working in virtual clinical trials. Based on multiple parameters, such as number of studies conducted annually, investment associated with these studies, and the likely cost and time saving opportunities, we have provided an informed estimate on the likely evolution of the market over the period 2020-2050. The report also features the likely distribution of the current and forecasted opportunity across [A] different therapeutic areas (cardiovascular disorders, infectious disorders, metabolic disorders, neurological disorders, oncological disorders and others), [B] end-users (small-sized players, mid-sized players, large players and academia / others) [C] phase of development (phase I, phase II, phase III and phase IV) and [D] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of virtual clinical trials service providers market.

Chapter 14 is a collection of interview transcripts of discussions held with key stakeholders in this market. We have presented the details of our discussions with (in alphabetical order of company names) Phillipe Lemmens (Chief Operating Officer, Andaman7), Himanshu Verma (Founder and Chief Executive Officer, ConsilX), Rajesh Jain (Co-Founder, ConsilX) and Greg Erman (President and Chief Executive Officer, EmpiraMed).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Existing Constraints in Clinical Research
3.2.1. Increasing Complexity and Cost of Trials
3.2.2. Evolving Regulatory Standards
3.2.3. Patient Recruitment and Retention Challenges
3.2.4. Data Handling-related Concerns

3.3. Virtual Clinical Trials
3.3.1. Key Aspects of Virtual Clinical Trials
3.3.1.1. Study Design
3.3.1.2. Patient Recruitment and Retention
3.3.1.3. Remote Monitoring
3.4.1.4. Data Collection and Analysis

3.3.2. Advantages and Disadvantages of Virtual Clinical Trials

3.4. Emerging Trends in Clinical Drug Development
3.4.1. Innovative Trial Designs
3.4.2. Real-world Evidence
3.4.3. Patient Centricity
3.4.4. Big Data Analytics
3.4.5. Blockchain Technology
3.5. Future Perspectives

4. VIRTUAL CLINICAL TRIAL SERVICE PROVIDERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Virtual Clinical Trial Service Providers: Overall Market Overview
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Geography
4.2.4. Analysis by Type of Service Offered

5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Cambridge Cognition
5.2.1. Company Overview
5.2.2. Technology Overview
5.2.3. Recent Developments and Future Outlook

5.3. Center Point Clinical Services
5.3.1. Company Overview
5.3.2. Technology Overview
5.3.3. Recent Developments and Future Outlook

5.4. eClinicalHealth
5.4.1. Company Overview
5.4.2. Technology Overview
5.4.3. Recent Developments and Future Outlook

5.5. IQVIA
5.5.1. Company Overview
5.5.2. Technology Overview
5.5.3. Recent Developments and Future Outlook

5.6. Mytrus (Medidata Solutions)
5.6.1. Company Overview
5.6.2. Technology Overview
5.6.3. Recent Developments and Future Outlook

5.7. PanAmerican Clinical Research
5.7.1. Company Overview
5.7.2. Technology Overview
5.7.3. Recent Developments and Future Outlook

5.8. Science 37
5.8.1. Company Overview
5.8.2. Technology Overview
5.8.3. Recent Developments and Future Outlook

5.9. VirTrial
5.9.1. Company Overview
5.9.2. Technology Overview
5.9.3. Recent Developments and Future Outlook

6. CASE STUDY: VIRTUAL CLINICAL TRIAL-RELATED INITIATIVES OF BIG PHARMA PLAYERS
6.1. Chapter Overview
6.2. Virtual Clinical Trial-Related Initiatives of Big Pharma Players
6.2.1. Pfizer
6.2.1.1. Initial Approach and Key Learnings
6.2.1.2. Future Perspective

6.2.2. Johnson & Johnson
6.2.2.1. Initial Approach and Key Learnings
6.2.2.2. Future Perspective

6.2.3. Sanofi
6.2.3.1. Initial Approach and Key Learnings
6.2.3.2. Future Perspective

6.2.4. Novartis
6.2.4.1. Initial Approach and Key Learnings
6.2.4.2. Future Perspective

6.2.5. GlaxoSmithKline
6.2.5.1. Initial Approach and Key Learnings
6.2.5.2. Future Perspective

6.2.6. Amgen
6.2.6.1. Initial Approach and Key Learnings
6.2.6.2. Future Perspective

6.2.7. AstraZeneca
6.2.7.1. Initial Approach and Key Learnings
6.2.7.2. Future Perspective

7. CASE STUDY: TRADITIONAL VERSUS VIRTUAL CRO
7.1. Chapter Overview
7.2. Comparison between Traditional and Virtual CROs
7.3. Key Attributes of a Virtual CRO
7.4. The Virtual Operating Model 
7.5. Concluding Remarks

8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Virtual Clinical Trial Service Providers: Funding and Investment Analysis
8.3.1. Analysis by Year of Investment
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Most Active Players
8.3.5. Most Active Investors
8.4. Concluding Remarks

9. PARTNERSHIPS & COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Virtual Clinical Trial Service Providers: Partnership and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Focus Area Mentioned in Agreement
9.3.4. Analysis by Target Therapeutic Area Mentioned in Agreement
9.3.5. Analysis by Year of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships
9.3.7. Geographical Analysis
9.3.9. Intercontinental and Intracontinental Agreements

10. COVID-19 IMPACT
10.1. Chapter Overview
10.2. Impact of COVID-19 on Clinical Trials
10.3. Impact on Future Opportunity for Virtual Clinical Trials Service Providers

11. CLINICAL TRIAL ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Virtual Clinical Trials: Clinical Trial Analysis
11.3.1. Analysis by Trial Registration Year
11.3.2. Analysis by Trial Phase
11.3.3. Analysis by Trial Status
11.3.4. Analysis by Trial Design
11.3.5. Analysis by Type of Sponsor
11.3.6. Analysis by Target Therapeutic Area
11.3.7. Geographical Analysis by Number of Registered Trials
11.3.8. Geographical Analysis by Number of Patients Enrolled

12. MARKET OPPORTUNITY ASSESSMENT
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050
12.3.1. Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area
12.3.2. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by End-user 
12.3.3. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase
12.3.4. Virtual Clinical Trials Service Providers Market Opportunity, 2020-2050: Distribution by Geography

12.4. Virtual Clinical Trial Services Market in North America, 2020-2050
12.4.1. Virtual Clinical Trial Services Market in North America: Distribution by Therapeutic Area, 2020-2050
12.4.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050
12.4.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies

12.4.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050
12.4.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies 

12.4.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050
12.4.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies 

12.4.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050
12.4.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies  

12.4.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050
12.4.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies 

12.4.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in North America, 2020-2050
12.4.6.1.1. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies 
12.4.6.1.2. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies 
12.4.6.1.3. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies 
12.4.6.1.4. Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies 

12.4.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in North America, 2020-2050
12.4.7.1.1. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies 
12.4.7.1.2. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies 
12.4.7.1.3. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies 
12.4.7.1.4. Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies 

12.5. Virtual Clinical Trial Services Market in Europe, 2020-2050
12.5.1. Virtual Clinical Trial Services Market in Europe: Distribution by Therapeutic Area, 2020-2050
12.5.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050
12.5.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies
12.5.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050
12.5.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies 
12.5.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050
12.5.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies 
12.5.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050
12.5.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies 
12.5.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050
12.5.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies 
12.5.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050
12.5.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies 
12.5.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies 
12.5.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies 
12.5.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies 

12.5.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050
12.5.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies 
12.5.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies 
12.5.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies 
12.5.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies 

12.6. Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050
12.6.1. Virtual Clinical Trial Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2020-2050
12.6.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050
12.6.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050
12.6.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050
12.6.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050
12.6.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050
12.6.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050
12.6.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.6.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050
12.6.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies 
12.6.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies 
12.6.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies 
12.6.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies 

12.7. Virtual Clinical Trial Services Market in Rest of the World, 2020-2050
12.7.1. Virtual Clinical Trial Services Market in Rest of the World: Distribution by Therapeutic Area, 2020-2050
12.7.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050
12.7.1.1.1. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.1.1.2. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.1.1.3. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.1.1.4. Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.2.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050
12.7.2.1.1. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.2.1.2. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.2.1.3. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.2.1.4. Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.3.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050
12.7.3.1.1. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.3.1.2. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.3.1.3. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.3.1.4. Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.4.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050
12.7.4.1.1. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies

12.7.4.1.2. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.4.1.3. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.4.1.4. Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.5.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050
12.7.5.1.1. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.5.1.2. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.5.1.3. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.5.1.4. Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.6.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050
12.7.6.1.1. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.6.1.2. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.6.1.3. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.6.1.4. Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies 

12.7.7.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050
12.7.7.1.1. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies 
12.7.7.1.2. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies 
12.7.7.1.3. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies 
12.7.7.1.4. Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies 

13. CONCLUSION

14. INTERVIEW TRANSCRIPTS
14.1. Chapter Overview
14.2. ConsilX 
14.2.1. Interview Transcript: Himanshu Verma, Founder and Chief Executive Officer, ConsilX & Rajesh Jain, Co-Founder, ConsilX

14.3. EmpiraMed
14.3.1. Interview Transcript: Greg Erman, President and Chief Executive Officer, EmpiraMed

14.4. Andaman7
14.4.1. Interview Transcript: Phillipe Lemmens, Chief Operating Officer, Andaman7

14.5. uMotif
14.5.1. Interview Transcript: Jonathan Moshinsky, Head of Market Strategy, uMotif

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Existing Constraints in Clinical Research
Figure 3.2 Drug Development Costs: Historical Trend (USD Million)
Figure 3.3 Virtual Trial Model
Figure 3.4 Umbrella Trial and Basket Trial Designs: Key Differences
Figure 3.5 Generating Evidence from Real World Data
Figure 3.6 Patient Centric Approach to Clinical Trials
Figure 3.7 Role of Big Data in Clinical Research
Figure 4.1 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
Figure 4.2 Virtual Clinical Trial Service Providers: Distribution by Company Size
Figure 4.3 Virtual Clinical Trial Service Providers: Distribution by Geography
Figure 4.4 Virtual Clinical Trial Service Providers: Distribution by Type of Services Offered
Figure 6.1 Initiatives by Big Pharma Players in Virtual Trials Domain: Timeline of Events
Figure 8.1 Funding and Investment Analysis: Heat Map based on Year of Establishment and Type of Funding, 2014-2020
Figure 8.2 Funding and Investment Analysis: Cumulative Number of Instances, 2014-2020
Figure 8.3 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
Figure 8.4 Funding and Investment Analysis: Yearly Distribution of Number of Instances and Amount Invested, 2014-2020 (USD Million)
Figure 8.5 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2020 (USD Million)
Figure 8.6 Funding and Investment Analysis: Distribution of Amount Invested by Type of Domain, 2014-2020 (USD Million)
Figure 8.7 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2014-2020
Figure 8.8 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2014-2020
Figure 8.9 Funding and Investment Analysis: Summary of Investments, 2014-2020 (USD
Figure 8.10 Funding and Investment Analysis: Most Active Players
Figure 8.11 Funding and Investment Analysis: Most Active Investors
Figure 8.12 Funding and Investment Summary
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-2020
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2014-2020
Figure 9.4 Partnerships and Collaborations: Distribution by Application Mentioned in the Agreement
Figure 9.5 Partnerships and Collaborations: Distribution by Target Therapeutic Area Mentioned in the Agreement
Figure 9.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type 
Figure 9.7 Most Active Players: Distribution by Number of Partnerships 
Figure 9.8 Partnership and Collaborations: Geographical Distribution
Figure 9.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 11.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 11.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year
Figure 11.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 11.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 11.5 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator 
Figure 11.6 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Figure 11.7 Clinical Trial Analysis: Distribution by Trial Design
Figure 11.8 Clinical Trial Analysis: Distribution by Trial Allocation Model Used
Figure 11.9 Clinical Trial Analysis: Distribution by Trial Masking Adopted
Figure 11.10 Clinical Trial Analysis: Distribution by Intervention
Figure 11.11 Clinical Trial Analysis: Distribution by Trial Purpose
Figure 11.12 Clinical Trial Analysis: Distribution by Time Perspective
Figure 11.13 Clinical Trial Analysis: Geographical Distribution by Number of Clinical Trials
Figure 11.14 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population 
Figure 11.15 Clinical Trial Analysis: Geographical Distribution by Distribution by Number of Trials and Trial Status 
Figure 11.16 Clinical Trial Analysis: Geographical Distribution by Distribution by Enrolled Patient Population and Trial Status 
Figure 12.1 Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050 (USD Million)
Figure 12.2 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area (USD Million)
Figure 12.3 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by End-User (USD Million)
Figure 12.4 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase (USD Million)
Figure 12.5 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Geography (USD Million)
Figure 12.6 Virtual Clinical Trial Services Market in North America, 2020-2050 (USD Million)
Figure 12.7 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.8 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North   America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.9 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.10 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.11 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.12 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.13 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.14 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.15 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.16 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.17 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.18 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.19 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.20 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.21 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.22 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.23 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.24 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.25 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.26 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.27 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.28 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.29 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.30 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.31 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.32 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.33 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.34 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.35 Virtual Clinical Trial Services Market in Europe, 2020-2050 (USD Million)
Figure 12.36 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.37 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.38 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.39 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.40 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.41 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.42 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.43 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.44 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.45 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.46 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.47 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.48 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.49 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.50 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.51 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.52 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.53 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.54 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.55 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.56 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.57 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.58 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.59 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.60 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.61 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.62 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.63 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.64 Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050 (USD Million)
Figure 12.65 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.66 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.67 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.68 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.69 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.70 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.71 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.72 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.73 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.74 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.75 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.76 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.77 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.78 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.79 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.80 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.81 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.82 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.83 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.84 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.85 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.86 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.87 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.88 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.89 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.90 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.91 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.92 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.93 Virtual Clinical Trial Services Market in Rest of the World, 2020-2050 (USD Million)
Figure 12.94 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.95 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.96 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.97 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.98 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.99 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.100 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.101 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.102 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.103 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.104 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.105 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.106 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.107 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.108 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.109 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.110 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.111 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.112 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.113 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.114 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.115 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.116 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.117 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Figure 12.118 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Figure 12.119 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Figure 12.120 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Figure 12.121 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)

List Of Tables

Table 4.1 Virtual Clinical Trials: List of Service Providers
Table 4.2 Virtual Clinical Trial Service Providers: Information on Type of Services Offered
Table 5.1 Cambridge Cognition: Company Snapshot
Table 5.2 Cambridge Cognition: Recent Developments and Future Outlook
Table 5.3 Center Point Clinical Services: Company Snapshot
Table 5.4 Center Point Clinical Services: Recent Developments and Future Outlook
Table 5.5 eClinicalHealth: Company Snapshot
Table 5.6 eClinicalHealth: Recent Developments and Future Outlook
Table 5.7 IQVIA: Company Snapshot
Table 5.8 IQVIA: Recent Developments and Future Outlook
Table 5.9 Mytrus (Medidata Solutions): Company Snapshot
Table 5.10 Mytrus (Medidata Solutions): Recent Developments and Future Outlook
Table 5.11 PanAmerican Clinical Research: Company Snapshot
Table 5.12 PanAmerican Clinical Research: Recent Developments and Future Outlook
Table 5.13 Science 37: Company Snapshot
Table 5.14 Science 37: Recent Developments and Future Outlook
Table 5.15 VirTrial: Company Snapshot
Table 5.16 VirTrial: Recent Developments and Future Outlook
Table 6.1 Initiatives in Virtual Trials Domain: Big Pharma Analysis
Table 6.2 Virtual Clinical Trial Sponsors: List of Pharma Players
Table 8.1 Virtual Clinical Trial Service Providers: Funding and Investments, 2014-2020
Table 8.2 Funding and Investment Analysis: Summary of Investments
Table 9.1 Virtual Clinical Trial Service Providers: Partnership and Collaborations, 2014-2020
Table 15.1 Virtual Clinical Trial Service Providers: Distribution by Year of Establishment
Table 15.2 Virtual Clinical Trial Service Providers: Distribution by Company Size
Table 15.3 Virtual Clinical Trial Service Providers: Distribution by Geography
Table 15.4 Virtual Clinical Trial Service Providers: Distribution by Type of Services Offered
Table 15.5 Initiatives by Big Pharma Players in Virtual Trials Domain: Timeline of Events
Table 15.6 Road Map for Traditional CRO's to Transition to Virtual CRO
Table 15.7 Funding and Investment Analysis: Heat Map based on Year of Establishment and Type of Funding, 2014-2020
Table 15.8 Funding and Investment Analysis: Cumulative Number of Instances, 2014-2020
Table 15.9 Funding and Investment Analysis: Cumulative Amount Invested, 2014-2020 (USD Million)
Table 15.10 Funding and Investment Analysis: Yearly Distribution of Number of Instances and Amount Invested, 2014-2020 (USD Million)
Table 15.11 Funding and Investment Analysis: Distribution by Amount Invested, 2014-2020 (USD Million)
Table 15.12 Funding and Investment Analysis: Distribution of Amount Invested by Type of Domain, 2014-2020 (USD Million)
Table 15.13 Funding and Investment Analysis: Distribution of Number of Instances by Type of Funding, 2014-2020
Table 15.14 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2014-2020
Table 15.15 Funding and Investment Analysis: Summary of Investments, 2014-2020 (USD Million)
Table 15.16 Funding and Investment Analysis: Most Active Players
Table 15.17 Funding and Investment Analysis: Most Active Investors
Table 15.18 Funding and Investment Summary
Table 15.19 Partnership and Collaboration: Cumulative Year-wise Trend, 2014-2020
Table 15.20 Partnership and Collaboration: Distribution by Type of Partnership
Table 15.21 Partnership and Collaboration: Distribution by Year and Type of Partnership, 2014-2020
Table 15.22 Analysis by Focus Area Mentioned in Agreement
Table 15.23 Analysis by Target Therapeutic Area Mentioned in Agreement
Table 15.24 Analysis by Year of Partnership and Type of Partner
Table 15.25 Most Active Players: Analysis by Number of Partnerships
Table 15.26 Geographical Analysis
Table 15.27 Intercontinental and Intracontinental Agreements
Table 15.28 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 15.29 Clinical Trial Analysis: Distribution by Trial Phase
Table 15.30 Clinical Trial Analysis: Distribution by Trial Status
Table 15.31 Clinical Trial Analysis: Distribution by Type of Sponsor
Table 15.32 Clinical Trial Analysis: Distribution by Target Therapeutic Area
Table 15.33 Clinical Trial Analysis: Distribution by Trial Design
Table 15.34 Virtual Clinical Trial Service Providers: Overall Market Opportunity, 2020-2050 (USD Million)
Table 15.35 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Therapeutic Area (USD Million)
Table 15.36 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by End-User (USD Million)
Table 15.37 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Trial Phase (USD Million)
Table 15.38 Virtual Clinical Trial Service Providers Market Opportunity, 2020-2050: Distribution by Geography (USD Million)
Table 15.39 Virtual Clinical Trial Services Market in North America, 2020-2050 (USD Million)
Table 15.40 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.41 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.42 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.43 Virtual Clinical Trial Services Market for Cardiovascular Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.44 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.45 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.46 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.47 Virtual Clinical Trial Services Market for Infectious Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.48 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.49 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.50 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.51 Virtual Clinical Trial Services Market for Metabolic Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.52 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.53 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.54 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.55 Virtual Clinical Trial Services Market for Neurological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.56 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.57 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.58 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.59 Virtual Clinical Trial Services Market for Oncological Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.60 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.61 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.62 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.63 Virtual Clinical Trial Services Market Opportunity for Respiratory Disorders in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.64 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.65 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.66 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.67 Virtual Clinical Trial Services Market Opportunity for Other Therapeutic Areas in North America, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.68 Virtual Clinical Trial Services Market in Europe, 2020-2050 (USD Million)
Table 15.69 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.70 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.71 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.72 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.73 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.74 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.75 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.76 Virtual Clinical Trial Services Market for Infectious Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.77 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.78 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.79 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.80 Virtual Clinical Trial Services Market for Metabolic Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.81 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.82 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.83 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.84 Virtual Clinical Trial Services Market for Neurological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.85 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.86 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.87 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.88 Virtual Clinical Trial Services Market for Oncological Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.89 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.90 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.91 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.92 Virtual Clinical Trial Services Market for Respiratory Disorders in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.93 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.94 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.95 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.96 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Europe, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.97 Virtual Clinical Trial Services Market in Asia-Pacific, 2020-2050 (USD Million)
Table 15.98 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.99 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.100 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.101 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.102 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.103 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.104 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.105 Virtual Clinical Trial Services Market for Infectious Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.106 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.107 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.108 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.109 Virtual Clinical Trial Services Market for Metabolic Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.110 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.111 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.112 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.113 Virtual Clinical Trial Services Market for Neurological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.114 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.115 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.116 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.117 Virtual Clinical Trial Services Market for Oncological Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.118 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.119 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.120 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.121 Virtual Clinical Trial Services Market for Respiratory Disorders in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.122 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.123 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.124 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.125 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Asia-Pacific, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.126 Virtual Clinical Trial Services Market in Rest of the World, 2020-2050 (USD Million)
Table 15.127 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.128 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.129 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.130 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.131 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.132 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.133 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.134 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.135 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.136 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.137 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.138 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.139 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.140 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.141 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.142 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.143 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.144 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.145 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.146 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.147 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.148 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.149 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.150 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.151 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase I Studies (USD Million)
Table 15.152 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase II Studies (USD Million)
Table 15.153 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase III Studies (USD Million)
Table 15.154 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050: Share of Phase IV Studies (USD Million)
Table 15.155 Market Opportunity for Phase III Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.156 Market Opportunity for Phase IV Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.157 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.158 Market Opportunity for Phase I Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.159 Market Opportunity for Phase II Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.160 Market Opportunity for Phase III Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.161 Market Opportunity for Phase IV Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.162 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.163 Market Opportunity for Phase I Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.164 Market Opportunity for Phase II Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.165 Market Opportunity for Phase III Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.166 Market Opportunity for Phase IV Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.167 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.168 Market Opportunity for Phase I Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.169 Market Opportunity for Phase II Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.170 Market Opportunity for Phase III Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.171 Market Opportunity for Phase IV Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.172 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.173 Market Opportunity for Phase I Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.174 Market Opportunity for Phase II Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.175 Market Opportunity for Phase III Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.176 Market Opportunity for Phase IV Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.177 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.178 Market Opportunity for Phase I Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.179 Market Opportunity for Phase II Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.180 Market Opportunity for Phase III Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.181 Market Opportunity for Phase IV Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.182 Virtual Clinical Trial Services Market for Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.183 Market Opportunity for Phase I Studies of Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.184 Market Opportunity for Phase II Studies of Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.185 Market Opportunity for Phase III Studies of Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.186 Market Opportunity for Phase IV Studies of Cardiovascular Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.187 Virtual Clinical Trial Services Market for Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.188 Market Opportunity for Phase I Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.189 Market Opportunity for Phase II Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.190 Market Opportunity for Phase III Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.191 Market Opportunity for Phase IV Studies of Infectious Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.192 Virtual Clinical Trial Services Market for Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.193 Market Opportunity for Phase I Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.194 Market Opportunity for Phase II Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.195 Market Opportunity for Phase III Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.196 Market Opportunity for Phase IV Studies of Metabolic Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.197 Virtual Clinical Trial Services Market for Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.198 Market Opportunity for Phase I Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.199 Market Opportunity for Phase II Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.200 Market Opportunity for Phase III Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.201 Market Opportunity for Phase IV Studies of Neurological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.202 Virtual Clinical Trial Services Market for Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.203 Market Opportunity for Phase I Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.204 Market Opportunity for Phase II Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.205 Market Opportunity for Phase III Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.206 Market Opportunity for Phase IV Studies of Oncological Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.207 Virtual Clinical Trial Services Market for Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.208 Market Opportunity for Phase I Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.209 Market Opportunity for Phase II Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.210 Market Opportunity for Phase III Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.211 Market Opportunity for Phase IV Studies of Respiratory Disorders in Rest of the World, 2020-2050 (USD Million)
Table 15.212 Virtual Clinical Trial Services Market for Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.213 Market Opportunity for Phase I Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.214 Market Opportunity for Phase II Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.215 Market Opportunity for Phase III Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)
Table 15.216 Market Opportunity for Phase IV Studies of Other Therapeutic Areas in Rest of the World, 2020-2050 (USD Million)

List Of Company

The following companies and organizations have been included in the report.

  1. Academic Medical Center Amsterdam
  2. ACRP
  3. Advarra
  4. AiCure
  5. Alacris Theranostics
  6. AliveCor
  7. Andaman7
  8. Aparito
  9. AstraZeneca
  10. Atlantic General Hospital
  11. BARDA
  12. BetterLife
  13. BioIntelliSense 
  14. Boehringer Ingelheim
  15. CAIMED
  16. Cambridge Cognition
  17. Cancer Hope Network
  18. Castor
  19. Center Point Clinical Services
  20. City of Hope Medical Center
  21. Click Therapeutics
  22. ClinCloud Tech
  23. Clinerion
  24. Clinical Ink
  25. Clinical Trials Transformation Initiative
  26. ClinOne
  27. ConsilX
  28. Covance
  29. Covance
  30. Cquentia
  31. Ctrl Group
  32. Datavant
  33. Delve Health 
  34. Dreem
  35. DxTerity
  36. eClinicalHealth
  37. Elektra Labs
  38. Eli Lilly
  39. EmpiraMed
  40. ERT
  41. Evidation
  42. Foundation Medicine
  43. GI Partners
  44. Harte Group
  45. Healint
  46. i3 Consult
  47. iClinical
  48. IDD Research
  49. IQVIA
  50. ISBX
  51. Jeeva Informatics
  52. Kinsights
  53. KiwiTech
  54. LabCorp
  55. LabCorp
  56. Medable
  57. Medikit
  58. Medocity
  59. Medpoint Digital
  60. monARC Bionetworks
  61. MRN
  62. Myovant Sciences
  63. Medidata Solutions
  64. Novartis
  65. ObvioHealth
  66. Otsuka Pharmaceutical
  67. PanAmerican Clinical Research
  68. PPMD
  69. Redox
  70. Roivant
  71. Sage Bionetworks
  72. Sanofi
  73. Sanofi
  74. Sarcoma Alliance
  75. Science 37
  76. Signant Health
  77. SnapIoT
  78. Studies&Me
  79. Synevo Central Labs
  80. Synexus
  81. THREAD Research
  82. Transparency Life Sciences
  83. UBC
  84. UCB
  85. Unnamed CRO
  86. Unnamed Pharmaceutiical Company
  87. Virtrial
  88. VisualDx
  89. Vsee
  90. Wellcome Trust 
  91. xCures

The complete list of companies and organizations included in the report is available on request.

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com